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Abstract 
A rare outcome following exposure to hepatitis C virus (HCV) is a lack of observable infection as 
clinically measured by HCV RNA or HCV recognising antibodies.  The population who exhibit this trait 
is termed exposed uninfected (EU).  Increasing evidence has refined characterisation of these 
individuals, distinct from those who become infected but spontaneously clear HCV.   Study of the EU 
population is highly pertinent for the discovery of antiviral mechanisms of resistance that can reveal 
antiviral therapeutic strategies.   
This review provides an overview of similarities and differences of the EU population relative to 
spontaneous resolvers and the majority whom develop chronic HCV infection, and focusses on 
possible mechanisms of resistance including innate and adaptive immunity, genetics and lipid 
interactions. 
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Introduction 
Hepatitis C virus (HCV) infection is  (1) a major global public health problem that can result in 
cirrhosis, liver cancer and death  with estimates of prevalence of antibodies against HCV (anti-HCV)  
ranging between 1.3 – 2.1 % (2).  Injection drug use is the dominant risk factor for HCV transmission 
in economically developed countries. Longer duration of injecting drug use  is associated with 
increased  prevalence of HCV infection (64 – 94% HCV anti-HCV positive) (3,4).   Epidemiological data 
indicates that globally  60 – 80% of people who inject drugs (PWIDs) are anti-HCV positive, with over 
80% prevalence in  12 countries (5).   This equates to approximately 10 million PWIDs who are anti-
HCV positive worldwide, with an estimated 1.6 million in China, 1.5 million in the United States of 
America, and 1.3 million in Russia (5).   
There is evidence that a small proportion of PWIDs remain HCV RNA and anti-HCV negative despite 
their history of repeated exposure to HCV through sharing of injecting needles and other 
paraphernalia.  Our group and others have previously characterised this cohort of PWIDs defining 
them as  ‘exposed uninfected’ (EU) (6–10).  The phenotype of repeated exposure to HCV without the 
development of infection is of considerable interest because it suggests these individuals are in some 
way resistant to HCV infection.  This review considers the phenotypic definitions of the EU cohort, 
and the distinct immunological and genetic features that characterise the EU group to gain insights 
into possible mechanisms of HCV resistance. 
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Differences between HCV Exposed Uninfected (EU), Spontaneous Resolvers (SR) and those with 
chronic HCV (CHCV) 
Parenteral HCV exposure results in one of 3 different outcomes:  the majority of individuals develop 
chronic HCV infection (CHCV) with detectable anti-HCV and persisting HCV RNA,  while approximately 
20% of people spontaneously resolve infection  (SR) (11) with detectable anti-HCV but clearance of 
HCV RNA, and finally a minority, who despite similar viral exposure, remain uninfected (EU) lacking 
detectable anti-HCV and HCV RNA.  These 3 outcomes can be characterised by differing 
immunological and genetic profiles (Table 1). 
HCV ‘exposed uninfected’ designation 
HCV exposure without infection has been described by several groups.  While we have termed this 
cohort  ‘exposed uninfected’ (6), other groups describe a similar phenomenon  in both HCV and 
Human immunodeficiency virus (HIV) as ‘highly exposed seronegative (HESN)’ (12), ‘highly exposed 
persistently seronegative (13), repeatedly ‘exposed seronegative (ESN)’ (14).  For meaningful debate 
and understanding, there needs to be clarity about phenotypic nomenclature.   
Exposed uninfected individuals represent a distinct group  
In the absence of serological evidence for developing infection, HCV exposure can only be 
determined by probability based on the history of risk behaviour.   It is known that PWIDs who share 
needles or other injecting paraphernalia with individuals known to have HCV infection are at high risk 
of HCV exposure and that HCV sero-prevalence increases with duration of injection history (15,16) as 
the cumulative probability of actual exposure increases.   
The EU group therefore needs to be carefully distinguished from unexposed naïve cases by close 
scrutiny of the probability of actual HCV exposure.   EU groups are practically defined as individuals 
whose test results are serially negative for anti-HCV and HCV RNA on at least 2 occasions, more than 
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6 months apart, in the context of ongoing high risk of HCV exposure, typically through injection drug 
use and sharing of injection paraphernalia (7,17).   The probability of true HCV exposure has mostly 
been determined on the basis of risk questionnaires.  An example utilising exceptional high-risk 
behaviours was described by Sugden et al, using a composite risk index for HCV exposure based on a 
time dependent cox-regression analysis of 14 separate weighted risk factors of risk behaviours and 
demographics (18).  Significantly higher composite risk scores were found in those that subsequently 
became infected.  However, within the uninfected group there were individuals that remained 
uninfected despite high risk behavioural profiles.  Separation of the uninfected group’s risk into 
tertiles (two points that divide data into three equal parts) indicated that those in the highest tertile 
had a pattern of risk actually higher than that observed in subjects who subsequently become 
infected (18).  Thus based on statistical models it is highly probable that these subjects had been 
exposed to HCV but despite this remained uninfected.   
An alternative definition of HCV exposure in EUs is the presence of HCV specific immunological 
responses (18) in the absence of anti-HCV or HCV RNA.  T cell responses can be measured to arrays of 
HCV peptides spanning structural and non-structural (NS) viral proteins, and are a marker of 
immunological exposure to HCV.   ELISpot is a technique employed for detection and analysis of 
individual cells that secrete  cytokines in response to in-vitro stimulation with specific antigens (in 
this case HCV peptides)(19) and is highly sensitive allowing for detection of as few as one cell in 
100,000 (20).  Cellular IFN-γ production is used as a readout of single cell activation with individual 
spots representing  each  cytokine secreting cell (20).  Using ELISpot up to 60% of high risk individuals 
have detectable HCV-specific T cell responses (6).   
Both definitions of HCV exposure have their flaws, with risk stratification according to injection 
history dependent on self-reported behaviours, and immunological definition potentially excluding 
cases who have alternative pathways of resistance and who don’t mount a T cell response despite 
viral exposure. Despite these limitations it is clear that in some individuals repeated parenteral 
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exposure to HCV through drug use does not result in infection becoming established and defining 
mechanisms of resistance in these cases is a key question for HCV research.  
 
Immunological resistance to HCV  
Given the high prevalence of T cell responses in the EU cohort, immunological mechanisms may be 
an important component of HCV resistance and the data suggesting differences in adaptive and 
innate immune responsiveness in EU compared to others is reviewed here.  
a) adaptive immune responses 
i. T Cells  
Spontaneous resolution of HCV inf ction is associated with robust T cell responses (21,22) 
and early, vigorous and multi-specific T cell responses targeting multiple viral epitopes 
appear crucial for spontaneous clearance (reviewed in (23)).  Conversely, an ineffective early 
cell-mediated response may result in the development of chronic HCV infection (24).  In SRs  
viral clearance is dependent on a complex set of viral-host interactions such as young age 
(25); females respond better than males (26), host immun  response and genetics, 
neutralising antibodies, and viral specific factors that include  genotypes, and diversity of 
quasispecies (27).   
Partial protective immunity after spontaneous resolution of HCV infection has been reported, 
with lower rates of HCV reinfection than would be expected in a matched uninfected 
population (28).  Detectable HCV-specific T cell responses remain for many years after 
spontaneous clearance (29) but their role in providing this partial protection has not been 
established.  
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In exposed uninfected cases up to 60% have demonstrable T cell responses (6), often to 
multiple viral antigens, but these responses are typically much weaker than those seen in SR 
(7,8,17).  Furthermore these T cell responses wane rapidly on cessation of injection drug use, 
and seem to require continued HCV exposure as a consequence of ongoing injection drug use 
to be maintained (30).  HCV specific cytotoxic T cell responses have been reported in 
imprisoned PWIDs  in association with transient hepatitis C viraemia that cleared without 
seroconversion (reviewed in (31)).  Similar HCV-specific T cell immune responses have been 
described in avireamic and seronegative family members of HCV infected individuals (32,33) 
and in healthcare workers following needle stick exposure to HCV  with evidence of an early 
T cell response induced in the absence of detectable anti-HCV or HCV RNA (34).  Overall 
these studies suggest that low dose exposure to HCV can prime HCV specific T cells and that 
repeated exposure can maintain that response (32,33,35) so that the frequency and dose of 
HCV exposure may influence any resulting degree of protection.  
The degree to which T cell responses confer protection in EUs is controversial.  A nested case 
control series from a prospectively studied cohort of PWIDs in Australia revealed no 
differences in T cell responses assessed by HCV-specific IFN-γ ELISpot, and HCV-specific CD4 T 
effector responses  between those who developed incident HCV infection compared to those 
who remained uninfected (EU) suggesting that whilst HCV-specific cellular immunity is 
prevalent in EU subjects it did not correlate with protection in their cohort (36).    
In keeping with this lack of correlation between demonstrable T cell responses and 
protection from HCV infection,  other studies have shown clearance of low levels of HCV 
viraemia without developing anti-HCV antibodies can occur in the absence of any 
demonstrable T cell immune responses (37,38).    
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In conclusion, whilst HCV-specific T cell immunological responses do provide good evidence 
of viral exposure, their role in conferring any protection from infection remains unproven, 
which suggests that there are other mechanisms involved in resistance to HCV infection.  
ii. B cells and anti-HCV mediated protection  
There is growing evidence that a robust anti-envelope antibody response can contribute 
significantly to viral clearance in acute infection (39) with the rapid onset of anti-HCV capable 
of neutralizing diverse strains of HCV being associated with clearance (40).  Furthermore, in 
vitro and in vivo studies have suggested that broadly neutralizing antibodies may contribute 
to resolution of infection even once HCV has become established (41,42).   Studies in 
chimpanzees utilising HCV neutralizing antibodies have indicated that viral replication can be 
delayed after challenging chimpanzees with pre-existing anti-HCV (43).  Robust neutralising 
antibody responses not identified by conventional HCV antibody assays may therefore 
contribute to HCV resistance in EUs.  We recently reported on finding significant IgG 
reactivity to HCV envelope proteins in 20 of 42 HCV antibody and HCV RNA negative EU cases, 
with 6 of them showing evidence of a significant virus neutralizing effect (44).   IgG from the 
neutralizing samples did not compete for binding sites with several well-characterized 
antibodies to known conformational epitopes on the E2 glycoprotein, suggesting novel 
epitopes may be targeted (44).  This is the only report to date of HCV-specific humoral 
immune responses in exposed uninfected injection drug users.  Current work seeks to 
identify if humoral responses correlate with the presence of T cell responses.  The presence 
of specific anti-envelope antibodies provides further confirmation of HCV exposure in these 
cases and is a plausible, but as yet unproven, mechanism by which some of these subjects 
may have resisted HCV infection following a low dose inoculation.  
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b) Innate immunity 
The innate immune system is the first line of defence against viral illness with the potential to 
prevent infection as well as facilitate subsequent adaptive immune responses and modify 
outcome of established infection.  Natural killer (NK) cells are considered the principal innate 
effectors and when activated can kill either directly via the release of granzyme and perforin 
containing cytotoxic granules or via cytokines such as IFN-γ. NK cells also act indirectly by 
influencing the activation and/or trafficking of other key immune cell populations, including T 
cells, to promote adaptive immune responses.  
Natural Killer cells are highly enriched in the liver in comparison to peripheral blood  (45).   NK 
cell activation is tightly controlled through a complex balance of activating and inhibitory 
receptors, with inhibitory NK receptors (NKRs) in steady-state conditions dominating signals from 
activating receptors, to safeguard from NK cell reactivity toward normal, healthy cells.  The main 
classes of NKRs are the predominantly inhibitory killer immunoglobulin-like receptors (KIR), the 
natural killer group 2 (NKG2) family of inhibitory (NKG2A) and activatory (NKG2C/D) isoforms, 
and the activating natural cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46.   
There is increasing evidence to support a key role for innate immune responses in EU cases.  A 
study looking at serum cytokine profiles in EU cases found significantly elevated levels of the pro-
inflammatory innate immune cytokine interleukin-6 and chemokine interleukin-8 in EU’s 
compared to those with chronic HCV, spontaneous resolvers or healthy controls (46).  A genetic 
study of the NK cell KIR receptors identified homozygosity for KIR2DL3:HLA-C1, which is linked to 
a readily activated NK cell phenotype (47), to be associated with the resistance to HCV infection 
seen in EU cases (48).  Of interest, the IL28B variant strongly associated with spontaneous 
resolution of HCV infection and a favourable treatment outcome was not found to be associated 
with these EU cases indicating that EU individuals are a distinct population from patients who 
spontaneously resolve HCV infection (48). 
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More recently studies have reported phenotypic and functional differences in NK cells in high-
risk cohorts that do not develop HCV infection.  In the first HCV seronegative PWIDs were shown 
to have increased levels of KIR2DL3
+
NKG2A
−
 NK cells compared to PWIDs with chronic or 
resolved HCV infection and these cells were not susceptible to HLA-E mediated inhibition (49).  
The strongest evidence to date comes from a prospectively studied cohort of seronegative 
PWIDs in Australia (36).  This nested case-control series studied 28 previously seronegative cases 
who seroconverted (incident cases of HCV) matched by demographics and risk behaviour to 28 
EU subjects who remained seronegative on follow up.  Samples were assayed for NK cell 
phenotypes and function before and after incident HCV infection to seek correlates with ongoing 
resistance to HCV in those who remained uninfected.  Sustained NK cell activation was found to 
contribute to protection against HCV infection with significantly higher numbers of both 
activated and cytotoxic cells found in the EU subjects together with higher frequencies of 
interferon gamma (IFN-γ) producing NK cells.  In contrast, no correlation with HCV-specific T cell 
responses and ongoing protection was identified.  
  
c) Other possible mechanisms of HCV resistance 
i. Genetic  
To date genetic studies in EU cases have been limited by the relatively small cohorts identified 
and reported on, so that studies have focussed on specific candidate genes.  Further 
collaborative investigations combining different EU cohorts will be needed to undertake any 
appropriately powered genome wide association study.  Candidate genes include those that 
influence the host innate/and or adaptive immune responses as well as those encoding HCV 
receptor molecules.   
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We have previously shown an association between the variant IL-12B C allele and resistance to 
HCV infection in EU cases (50).  This variant is associated with higher IL-12 production (51)  and 
thus may be of relevance in promoting effective anti-viral immune responses.  As described in 
the section on innate immune responses, a study on the genetics of NK cell KIR receptors 
identified a variant associated with a readily activated NK cell phenotype (KIR2DL3:C1 
homozygotes) (47), to be associated with the resistance to HCV infection seen in EU cases (48). 
HCV entry into hepatocytes is a complex multi-step process that involves a number of host 
factors and co-receptors including  CD81, Scavenger receptor class B member 1 (SRB1), the tight 
junction proteins claudin 1, 6 and 9 and occludin as well as  epidermal growth factor receptor 
(EGFR), Ephrin receptor A2 (EphA2),  transferrin receptor 1 (TfR1), Niemann-Pick C1-like 1 
(NPC1L1) and others (reviewed in (52)).    
CD81 appears to be very highly conserved with no genetic alterations found in a study of EU 
cases, HCV infected cases and controls (53).  Studies reported on a French cohort of HIV infected 
PWIDs with and without HCV infection (the HCV negative cases were considered EU) looked at 
sequencing findings in 22 EU cases and found no alteration in Claudin-1 (54), but did find 
heterozygous variants in claudin-6 and occludin in one case and two heterozygous variants in 
SRB-1 in another (55).  The relevance of these to resistance to HCV is unclear as detailed study 
showed that the variations in Claudin-6 and occludin identified did not confer resistance to HCV 
infection in an in-vitro model (56).  
  
ii) Lipids and HCV resistance 
HCV interacts with host lipid metabolism at all stages of the viral lifecycle - from attachment and 
entry into hepatocytes, to replication and assembly of new viral particles.  Circulating HCV is 
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associated with lipoproteins as complex ‘lipoviral particles’ (LVP) (57) which contain viral RNA, viral 
proteins, and host apolipoprotein constituents including apoB, apoE, apoA1, and apoC (58).  Growing 
evidence suggests that the LVP lipid and apolipoprotein components facilitate viral attachment to 
host cells by binding to cellular lipoprotein receptors and that the exchangeable apoE appears to be 
crucial for infectivity at the attachment step and at masking envelope glycoproteins from neutralising 
antibodies (59).  HCV replication takes place on lipid droplets with co-localization of core protein and 
non-structural NS5A to the lipid droplet.  Production of infectious HCV is dependent on hepatocyte 
machinery for the export of very low density lipoproteins (VLDL) (60). 
Thus evidence points toward a key role for lipid metabolism in the HCV lifecycle, and the close 
association with lipids and lipoproteins contributes to HCVs ability to evade the host’s immune 
surveillance.  Given this co-dependency on host lipid pathways, it is plausible that any mechanism 
that would disrupt the LVP formation would potentially reduce the viral infectivity and influence 
outcome following HCV exposure.  
Recently reported, but preliminary, data using lipidomics profiling demonstrated that the HCV 
resistant EU phenotype was clearly distinct from HCV susceptible individuals (61).  The role of lipids 
and lipid pathways in conferring HCV resistance is of interest but remains to be clarified. 
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Conclusion 
HCV exposure through injection drug use that does not result in infection is now well described in 
several countries.  This EU group exhibit resistance to HCV infection.  Detailed study to date suggests 
that this resistance is associated with an increased likelihood of having adaptive HCV-specific T and B 
cell responses, and an upregulated innate immune response.  Although the role these HCV-specific 
responses in conferring resistance to HCV infection remains ambiguous, detection of these responses 
confirms exposure in the absence of anti-HCV immunoglobulin or HCV RNA.  Possible mechanisms of 
resistance include upregulated innate immune responses including cytokine production, genetic 
variation, and altered lipid composition.  Current evidence suggests that the EU phenotype 
represents a spectrum, with varying degrees of resistance to HCV, possibly involving complex 
interactions between the inoculation size and frequency of HCV exposure with immune mediated 
pathways and other host factors such as genetic polymorphisms. 
The accurate characterisation of HCV exposed uninfected cases remains crucial to future studies and 
raises issues regarding the definition and confirmation of HCV exposure.  There remains a need for a 
universally agreed definition of exposure on the basis of probability derived from risk behaviours and 
duration of drug use, and / or evidence of immune responsiveness to HCV antigens, in order to 
define robust exposed uninfected cohorts to investigate pathways of HCV resistance.  A collaborative 
effort between groups using agreed definitions for EU cases could provide sufficient case numbers to 
undertake appropriately powered genetic studies.  A better understanding of all the factors 
associated with HCV resistance would be a major step forward in our understanding of the 
pathogenesis of this highly prevalent infection and in the search for alternative therapeutic strategies.        
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Tables 
Immunological and genetic differences based on HCV natural history 
 Exposed Uninfected Spontaneous resolution Chronic Infection 
Anti- HCV  Persistently negative positive positive 
HCV RNA Persistently not 
detected 
Transient positive, then 
persistently negative  
Two positive > 6 months 
apart 
Neutralising antibody 
responses 
Detected in 27% (62) Associated with early 
development of broadly 
neutralising antibody 
responses (40). 
And anti-host receptor 
(CD81) antibodies (63). 
Readily detectable 
neutralising antibodies in 
chronic infection 
T cell responses Detected in 60% but 
weak and wane on 
cessation of HCV 
exposure  (17) 
Early vigorous and broad 
anti HCV T cell responses 
typical (23). 
Initial T-cell responses 
weaken. Loss of CD4 T-
cell help, switch to a T-
reg cell profile, viral 
epitope escape, 
chronic antigen 
stimulation contribute 
to T-cell exhaustion 
(64). 
Genetic factors ↑ KIR2DL3 HLA-C (17). 
Not IFNλ3 (48) 
↑ KIR2DL3 HLA-C (17) 
IFLλ3 CC  (48) 
↓ KIR2DL3 HLA-C (17).  
IFNλ3 (48) 
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